<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Temsirolimus: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Temsirolimus: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Temsirolimus: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12008" href="/d/html/12008.html" rel="external">see "Temsirolimus: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F5017587"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Torisel</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868882"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Torisel</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F4932565"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, mTOR Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F4933701"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> For infusion reaction prophylaxis, premedicate with an H<sub>1</sub> antagonist (eg, diphenhydramine 25 to 50 mg IV) ~30 minutes prior to infusion; use with caution in patients unable to receive antihistamine premedication. Consider <i>Pneumocystis jirovecii</i> pneumonia (PJP) prophylaxis in patients receiving concomitant immunosuppressive or corticosteroid therapy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="350a8d6a-f381-4c28-8ea8-cc18e52d2de1">Endometrial cancer, locally advanced, recurrent, and/or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial cancer, locally advanced, recurrent, and/or metastatic (off-label use):</b>
<b>IV:</b> 25 mg once weekly; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21788564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21788564'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="045bd6ae-3edd-419a-aa75-2a643fc49694">Renal cell carcinoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Temsirolimus may be a treatment option for advanced renal cell carcinoma; however, other therapies are generally preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Atkins.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Atkins.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 25 mg once weekly; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17538086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17538086'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990870"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Hemodialysis: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). </p></div>
<div class="block doha drugH1Div" id="F50988156"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild hepatic impairment (bilirubin &gt;1 to 1.5 x ULN or AST &gt;ULN with bilirubin ≤ULN): Reduce dose to 15 mg once weekly and use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate-to-severe hepatic impairment (bilirubin &gt;1.5 x ULN): Use is contraindicated.</p></div>
<div class="block dot drugH1Div" id="F4933705"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hematologic toxicity: ANC &lt;1,000/mm<sup>3</sup> or platelets &lt;75,000/mm<sup>3</sup>: Withhold treatment until resolved; once resolved to ≤ grade 2, may reinitiate treatment with the dose reduced by 5 mg weekly; minimum dose: 15 mg weekly if adjustment for toxicity is needed.</p>
<p style="text-indent:-2em;margin-left:2em;">Nonhematologic toxicity: Any toxicity ≥ grade 3: Withhold treatment until resolves to ≤ grade 2; reinitiate treatment with the dose reduced by 5 mg weekly; minimum dose: 15 mg weekly if adjustment for toxicity is needed.</p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia: Initiation or alteration of insulin and/or oral hypoglycemic therapy may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">Hyperlipidemia: Initiation or alteration of antihyperlipidemic agents may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">Infusion/hypersensitivity reaction: Interrupt infusion and observe for 30 to 60 minutes (depending on the severity); treatment may be resumed with discretion at a slower infusion rate (up to 60 minutes); administer an H<sub>1</sub> antagonist (if not given as premedication) and/or an IV H<sub>2</sub> antagonist (eg, famotidine) ~30 minutes prior to resuming infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Interstitial lung disease: Consider withholding treatment for clinically significant respiratory symptoms until after recovery of symptoms or radiographic improvement. May require empiric treatment with corticosteroids and/or antibiotic therapy. Depending on the severity, may require temsirolimus discontinuation (Duran 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Nephrotic syndrome: Discontinue treatment.</p></div>
<div class="block doe drugH1Div" id="F4933702"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F4932576"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (35%), chest pain (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Pain (28%), headache (15%), insomnia (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (47%), pruritus (19%), nail disease (14%), xeroderma (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum glucose (89%; grades 3/4: 16%), increased serum cholesterol (87%; grades 3/4: 2%), hypertriglyceridemia (83%; grades 3/4: 44%), hypophosphatemia (49%; grades 3/4: 18%), hyperglycemia (26%), hyperlipidemia (≥30%), hypokalemia (21%; grades 3/4: 5%), weight loss (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Mucositis (41%), nausea (37%), anorexia (32%), diarrhea (27%), abdominal pain (21%; grades 3/4: 4%), constipation (20%), dysgeusia (20%), stomatitis (20%), vomiting (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (94%; grades 3/4: 20%), lymphocytopenia (53%; grades 3/4: 16%), thrombocytopenia (40%; grades 3/4: 1%; dose-limiting toxicity), decreased white blood cell count (32%; grades 3/4: 1%), anemia (≥30%), decreased neutrophils (19%; grades 3/4: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (68%; grades 3/4: 3%), increased serum AST (38%; grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (20%; grades 3/4: 3%; includes abscess, bronchitis, cellulitis, herpes simplex, herpes zoster)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (51%), back pain (20%), arthralgia (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (57%; grades 3/4: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (28%), cough (26%), epistaxis (12%), pharyngitis (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (24%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (7%), venous thromboembolism (2%; includes deep vein thrombosis and pulmonary embolism), pericardial effusion (1%), thrombophlebitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills (8%), depression (4%), convulsions (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Rectal hemorrhage (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (1%), wound infection (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (8%; including lacrimation disorder)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (10%), pneumonia (8%), upper respiratory tract infection (7%), pleural effusion (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Wound healing impairment (1%) </p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acute renal failure, angioedema, causalgia, cholecystitis, cholelithiasis, decreased glucose tolerance, extravasation reactions (with pain, swelling, warmth, erythema),  hypersensitivity reaction, interstitial pulmonary disease, intestinal perforation, pancreatitis, pneumonitis, rhabdomyolysis, seizure, Stevens-Johnson syndrome</p></div>
<div class="block coi drugH1Div" id="F4932572"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Bilirubin &gt;1.5 times the upper limit of normal (ULN).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): History of anaphylaxis after exposure to temsirolimus, sirolimus, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F4932573"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angioedema: Angioedema has been reported in patients taking mTOR inhibitors in combination with ramipril and/or amlodipine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Anemia, neutropenia, thrombocytopenia, and lymphocytopenia may commonly occur; grades 3 and 4 hematologic toxicity have been observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bowel perforation: Cases of bowel perforation (fatal) have occurred, usually presenting with abdominal pain, bloody stools, diarrhea, fever, or metabolic acidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperglycemia: Increases in serum glucose commonly occur during treatment. Use with caution in patients with diabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperlipidemia: Use with caution in patients with hyperlipidemia; may increase serum lipids (cholesterol and triglycerides).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/infusion reactions: Hypersensitivity/infusion reactions (eg, anaphylaxis, apnea, dyspnea, flushing, loss of consciousness, hypotension, and/or chest pain) have been reported. Infusion reactions may occur during the initial infusion (early in the infusion) or with subsequent infusions. Ensure appropriate supportive care is available. For severe infusion reactions, assess risk versus benefit of continued treatment. Use with caution in patients with hypersensitivity to temsirolimus, sirolimus (a metabolite), or polysorbate 80.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Treatment may result in immunosuppression, may increase risk of opportunistic infections and/or sepsis. <i>Pneumocystis</i>
<i>jirovecii</i> pneumonia (PJP) has been reported; some cases were fatal. Development of PJP may be associated with the use of concomitant corticosteroids or other immunosuppressive agents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney failure: Acute kidney failure with rapid progression (unrelated to disease progression) has been reported, including cases unresponsive to dialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Proteinuria: Proteinuria, including nephrotic syndrome, is associated with temsirolimus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Interstitial lung disease (ILD), sometimes fatal, has been reported; symptoms include dyspnea, cough, hypoxia and/or fever, although asymptomatic or mild cases may present; promptly evaluate worsening respiratory symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Wound healing: May be associated with impaired wound healing; use caution in the perioperative period.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS metastases/tumors: May be at increased risk for developing intracerebral bleeding (may be fatal).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Temsirolimus is predominantly cleared by the liver. Toxicities and deaths (including deaths due to progressive disease) were increased in patients with baseline bilirubin &gt;1.5 x ULN.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: An increased incidence of rash, infection, and dose interruptions have been reported in patients with renal insufficiency (CrCl ≤60 mL/minute) who received mTOR inhibitors for the treatment of renal cell cancer (Gupta 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulants: Patients who are receiving anticoagulant therapy may be at increased risk for developing intracerebral bleeding (may be fatal).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sunitinib: Combination therapy with temsirolimus and sunitinib has resulted in dose-limiting toxicities, including grade 3 or 4 rash, gout, and/or cellulitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Older adult patients may be more likely to experience adverse reactions, including diarrhea, edema, and pneumonia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should not be immunized with live viral vaccines during or shortly after treatment and should avoid close contact with recently vaccinated (live vaccine) individuals.</p></div>
<div class="block foc drugH1Div" id="F4934125"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Torisel: 25 mg/mL (1 mL) [contains alcohol, usp, polyethylene glycol (macrogol), polysorbate 80, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (1 mL)</p></div>
<div class="block geq drugH1Div" id="F4931466"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324137"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Temsirolimus Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $1,416.00 - $1,910.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Torisel Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $2,400.38</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868883"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Torisel: 25 mg/mL (1.2 mL) [contains alcohol, usp, polyethylene glycol (macrogol), polysorbate 80, propylene glycol]</p></div>
<div class="block adm drugH1Div" id="F4933706"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse over 30 to 60 minutes via an infusion pump (preferred). Use polyethylene-lined non-DEHP, non-PVC administration tubing (if PVC-containing administration set must be used, it should not contain DEHP). Administer through an inline polyethersulfone (PES) filter ≤5 micron; if set does not contain an inline filter, a PES end filter (0.2 to 5 micron) should be added (do not use both an inline and an end filter).</p>
<p style="text-indent:-2em;margin-left:2em;">Premedicate with an H<sub>1</sub> antagonist (eg, diphenhydramine 25 to 50 mg IV) ~30 minutes prior to infusion. Monitor during infusion; interrupt infusion for hypersensitivity/infusion reaction; monitor for 30 to 60 minutes; may reinitiate at a reduced infusion rate (over 60 minutes) with discretion, 30 minutes after administration of a histamine H<sub>1</sub> antagonist and/or a histamine H<sub>2</sub> antagonist (eg, famotidine). Administration should be completed within 6 hours of admixture.</p></div>
<div class="block hazard drugH1Div" id="F49132743"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F4931467"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Renal cell carcinoma, advanced: </b>Treatment of advanced renal cell carcinoma (RCC).</p></div>
<div class="block off-label drugH1Div" id="F49629876"><span class="drugH1">Use: Off-Label: Adult</span><p>Endometrial cancer, locally advanced, recurrent, and/or metastatic</p></div>
<div class="block mst drugH1Div" id="F4931461"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Temsirolimus may be confused with everolimus, sirolimus (conventional), sirolimus (protein bound), tacrolimus, temozolomide, tesamorelin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Temsirolimus requires a two-step dilution process prior to administration. The medication is supplied in a vial containing a total amount of 30 mg in a total volume of 1.2 mL (25 mg/mL). The vial must initially be diluted to 10 mg/mL (with provided 1.8 mL of diluent), then the intended dose should be withdrawn from the 10 mg/mL diluted vial (ie, 2.5 mL for a 25 mg dose) and further diluted for infusion in 250 mL sodium chloride 0.9%. Errors have occurred due to improper preparation.</p>
<p style="text-indent:-2em;margin-left:4em;">Temsirolimus, for the treatment of advanced renal cell cancer, is a flat dose (25 mg if no dosage reductions) and is not based on body surface area (BSA).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F4933684"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F4933683"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Temsirolimus may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Temsirolimus may enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described with concomitant sirolimus use. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, sirolimus concentrations may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Temsirolimus.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be decreased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Temsirolimus. Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inducers. If coadministration is unavoidable, increase temsirolimus dose to 50 mg per week. Resume previous temsirolimus dose after discontinuation of the strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be increased. Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inhibitors. If coadministration is unavoidable, decrease temsirolimus dose to 12.5 mg per week. Resume previous temsirolimus dose 1 week after discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): May decrease serum concentrations of the active metabolite(s) of Temsirolimus.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be decreased. Rifabutin may decrease the serum concentration of Temsirolimus.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: Temsirolimus may enhance the adverse/toxic effect of SUNItinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): May enhance the adverse/toxic effect of Temsirolimus. Temsirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Temsirolimus may decrease the serum concentration of Tacrolimus (Systemic). Temsirolimus may increase the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F4933687"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Grapefruit and grapefruit juice may increase the levels/effects of sirolimus. Management: Avoid grapefruit and grapefruit juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F53623777"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should be advised to avoid pregnancy and use effective contraception during treatment and for 3 months after the last temsirolimus dose. Patients with partners who could become pregnant should also use effective birth control during treatment and for 3 months after the last temsirolimus dose.</p></div>
<div class="block pri drugH1Div" id="F4932568"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on findings in animal reproduction studies and on the mechanism of action, in utero exposure to temsirolimus may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F4932571"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if temsirolimus is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 3 weeks following the last temsirolimus dose.</p></div>
<div class="block dic drugH1Div" id="F13194918"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid grapefruit juice (may increase the levels of the major metabolite, sirolimus).</p></div>
<div class="block mop drugH1Div" id="F4933708"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and platelets, serum glucose (baseline and periodic), serum cholesterol and triglycerides (baseline and periodic), liver function (baseline and periodic), renal function tests (baseline and periodic), urine protein (baseline and periodic); radiographic assessment by lung computed tomography scan or chest radiograph (baseline and periodic) even in absence of clinical respiratory symptoms.</p>
<p style="text-indent:0em;margin-top:2em;">Monitor for signs/symptoms of hypersensitivity and infusion reactions; monitor for signs/symptoms of infection, interstitial lung disease (or radiographic changes), hyperglycemia (excessive thirst, polyuria), bowel perforation (promptly evaluate any new or worsening abdominal pain or bloody stools), nephrotic syndrome, angioedema (if receiving concurrent ACE inhibitors or calcium channel blockers).</p>
<p style="text-indent:0em;margin-top:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F4934120"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Temsirolimus and its active metabolite, sirolimus, are targeted inhibitors of mTOR (mechanistic target of rapamycin) kinase activity. Temsirolimus (and sirolimus) bind to FKBP-12, an intracellular protein, to form a complex which inhibits mTOR signaling, halting the cell cycle at the G1 phase in tumor cells. Inhibition of mTOR blocks downstream phosphorylation of p70S6k and S6 ribosomal proteins. In renal cell carcinoma, mTOR inhibition also exhibits anti-angiogenesis activity by reducing levels of HIF-1 and HIF-2 alpha (hypoxia inducible factors) and vascular endothelial growth factor (VEGF). </p></div>
<div class="block phk drugH1Div" id="F4933693"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 172 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; via CYP3A4 to sirolimus (primary active metabolite) and 4 minor metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Temsirolimus: 17.3 hours; Sirolimus: 54.6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Temsirolimus: At end of infusion; Sirolimus: 0.5 to 2 hours after temsirolimus infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (78%); urine (4.6%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6875346"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Genxtor | Torisel</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Torisel | Torisell</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Torisel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21763973">
<a name="21763973"></a>Appleby L, Morrissey S, Bellmunt J, et al. Management of Treatment-Related Toxicity With Targeted Therapies for Renal Cell Carcinoma: Evidence-Based Practice and Best Practices. <i>Hematol Oncol Clin North Am</i>. 2011;25(4):893-915.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/21763973/pubmed" id="21763973" target="_blank">21763973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14990647">
<a name="14990647"></a>Atkins MB, Hidalgo M, Stadler WM, et al. Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma. <i>J Clin Oncol</i>. 2004;22(5): 909-918.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/14990647/pubmed" id="14990647" target="_blank">14990647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atkins.1">
<a name="Atkins.1"></a>Atkins MB. Overview of the treatment of renal cell carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18385198">
<a name="18385198"></a>Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus Safety Profile and Management of Toxic Effects in Patients With Advanced Renal Cell Carcinoma and Poor Prognostic Features. <i>Ann Oncol</i>. 2008;19(8):1387-1392.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/18385198/pubmed" id="18385198" target="_blank">18385198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16806903">
<a name="16806903"></a>Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. <i>Eur J Cancer</i>. 2006;42(12):1875-80. doi:10.1016/j.ejca.2006.03.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/16806903/pubmed" id="16806903" target="_blank">16806903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19229667">
<a name="19229667"></a>Dutcher JP, de Souza P, McDermott D, et al. Effect of Temsirolimus Versus Interferon-Alpha on Outcome of Patients With Advanced Renal Cell Carcinoma of Different Tumor Histologies. <i>Med Oncol</i>. 2009;26(2):202-209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/19229667/pubmed" id="19229667" target="_blank">19229667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21799472">
<a name="21799472"></a>Gupta S, Parsa VB, Heilbrun LK, et al. Safety and Efficacy of Molecularly Targeted Agents in Patients With Metastatic Kidney Cancer With Renal Dysfunction. <i>Anticancer Drugs</i>. 2011;22(8):794-800.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/21799472/pubmed" id="21799472" target="_blank">21799472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21234295">
<a name="21234295"></a>Hadoux J, Vignot S, De La Motte Rouge T. Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus. <i>Clin Med Insights Oncol</i>. 2010;4:143-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/21234295/pubmed" id="21234295" target="_blank">21234295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19581539">
<a name="19581539"></a>Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. <i>J Clin Oncol</i>. 2009;27(23):3822-3829.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/19581539/pubmed" id="19581539" target="_blank">19581539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17020981">
<a name="17020981"></a>Hidalgo M, Buckner JC, Erlichman C, et al. A Phase I and Pharmacokinetics Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Cancer. <i>Clin Cancer Res</i>. 2006;12(19):5755-5763.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/17020981/pubmed" id="17020981" target="_blank">17020981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17538086">
<a name="17538086"></a>Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. <i>N Engl J Med</i>. 2007;356(22):2271-2281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/17538086/pubmed" id="17538086" target="_blank">17538086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21444868">
<a name="21444868"></a>Maroto JP, Hudes G, Dutcher JP, et al. Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus. <i>J Clin Oncol</i>. 2011;29(13):1750-1756.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/21444868/pubmed" id="21444868" target="_blank">21444868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21788564">
<a name="21788564"></a>Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. <i>J Clin Oncol</i>. 2011;29(24):3278-3285.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/21788564/pubmed" id="21788564" target="_blank">21788564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15136596">
<a name="15136596"></a>Raymond E, Alexandre J, Faivre S, et al. Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer. <i>J Clin Oncol.</i> 2004;22(12):2336-2347.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/15136596/pubmed" id="15136596" target="_blank">15136596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temsirolimus-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Torisel.1">
<a name="Torisel.1"></a>Torisel (temsirolimus) [prescribing information]. Philadelphia, PA: Pfizer Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Torisel.2">
<a name="Torisel.2"></a>Torisel (temsirolimus) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10344 Version 335.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
